Osimertinib
Reading tools
Approved by the FDA on 13 November 2015, Osimertinib (Tagrisso®) is used in patients with distantly spread EGFR (epidermal growth factor receptor) T790M mutation-positive non-small cell lung cancer . Taken orally, Osimertinib acts through EGFR, like Necitumumab. By blocking the receptor called EGFR, it prevents cancer cell growth and formation of new blood vessels. Diarrhea, rash, dry skin and effects on the nails are its most frequently reported side effects.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.